Advances in nano-delivery of natural products for cancer therapy: mechanisms and translational strategies
Source abstract
Abstract
Abstract Cancer remains a major global health burden, with conventional monotherapies often limited by recurrence, therapeutic resistance, and systemic toxicity. Natural products, derived from diverse sources and characterized by distinct chemical structures, exhibit broad anticancer potential by modulating multiple molecular pathways. However, their clinical application is frequently constrained by poor solubility, low bioavailability, and chemical instability. Nano-delivery systems (NDS) have emerged as a promising strategy to address these limitations by improving pharmacokinetic properties, stabilizing labile compounds, and enabling co-delivery with conventional therapeutics, thereby supporting multimodal and synergistic interventions. This review provides a comprehensive overview of natural product-based NDS in cancer therapy, beginning with classification strategies and mechanistic frameworks, followed by an analysis of how NDS enhance pharmacological performance and facilitate integration into combination regimens. Finally, it highlights key translational challenges and opportunities, offering a foundation for the future development and clinical translation of natural product-based NDS.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Curcumin's Biomedical Applications · Flavonoids in Medical Research · Phytochemical compounds biological activities
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Mudanjiang Medical University
Guangzhou University of Chinese Medicine
Longgang Central Hospital
Funding
Long-gang District Medical and Health Technology Research Project · Research Project of the Fundamental Research Funds for Provincial Universities of Heilongjiang Province · Shenzhen Science and Technology Program · Institutional Research Talent Development Fund of Longgang Central Hospital
References (100+)
Show source-provided references
1. Expanding research in cancer epidemiology in journal of clinical oncology10.1200/JCO.23.02328 ↗
2. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth10.1016/j.ccell.2023.02.016 ↗
3. Cancer immune evasion, immunoediting and intratumour heterogeneity Nat.10.1038/s41577-024-01111-8 ↗
4. Natural products reverse cisplatin resistance in the hypoxic tumor microenvironment10.1016/j.canlet.2024.217116 ↗
5. A natural product-derived nanozyme regulator induced chemo-ferroptosis dual therapy in remodeling of the tumor immune microenvironment of hepatocellular carcinoma10.1016/j.cej.2024.148976 ↗
6. Emerging role of natural products in cancer immunotherapy10.1016/j.apsb.2021.08.020 ↗
7. Ultrasound-augmented enzyodynamic-Ca2+ overload synergetic tumor nanotherapy10.1016/j.biomaterials.2024.122513 ↗
8. Advances in cell membrane-based biomimetic nanodelivery systems for natural products10.1080/10717544.2024.2361169 ↗
9. New opportunities and challenges of natural products research: when target identification meets single-cell multiomics10.1016/j.apsb.2022.08.022 ↗
10. Integration of active ingredients from traditional chinese medicine with nano-delivery systems for tumor immunotherapy10.1186/s12951-025-03378-y ↗
11. Recent strategies in nanodelivery systems for natural products: a review10.1007/s10311-021-01276-x ↗
12. Advanced generation therapeutics: biomimetic nanodelivery system for tumor immunotherapy10.1021/acsnano.3c10212 ↗
13. A novel folate receptor-targeted curcumin nano-delivery system: a dual therapeutic strategy for precise inhibition of MRCKβ to suppress ovarian cancer proliferation and immune escape Mater.10.1016/j.mtbio.2025.102307 ↗
14. Engineering therapeutic scaffolds: integrating drug delivery with tissue regeneration
15. Recent advances in self-targeting natural product-based nanomedicines10.1186/s12951-025-03092-9 ↗
16. Recent advances in biomimetic nanodelivery systems for cancer immunotherapy10.1016/j.mtbio.2025.101726 ↗
17. Tissue-resident macrophage membrane-coated nanomedicine for targeted tumor therapy10.1021/acsnano.5c04463 ↗
18. Natural products for combating multidrug resistance in cancer10.1016/j.phrs.2024.107099 ↗
19. Strategies and lessons learned from total synthesis of taxol10.1021/acs.chemrev.2c00763 ↗
20. HIF-1α inhibition by MO-2097, a novel chiral-free benzofuran targeting hnRNPA2B110.1016/j.jare.2023.11.016 ↗
21. New drug discovery and development from natural products: advances and strategies10.1016/j.pharmthera.2024.108752 ↗
22. From plant to cancer drug: lessons learned from the discovery of taxol10.1039/D3NP00017F ↗
23. A concise enzyme cascade enables the manufacture of natural and halogenated protoberberine alkaloids10.1038/s41467-025-57280-0 ↗
24. Role of the sulfur-containing amino acid-ROS axis in cancer chemotherapeutic drug resistance10.1016/j.drup.2025.101238 ↗
25. Berberine derivative B68 promotes tumor immune clearance by dual-targeting BMI1 for senescence induction and CSN5 for PD-L1 degradation10.1002/advs.202413122 ↗
26. Morphologically transformable peptide nanocarriers coloaded with doxorubicin and curcumin inhibit the growth and metastasis of hepatocellular carcinoma10.1016/j.mtbio.2023.100903 ↗
27. Opportunities and challenges for co-delivery nanomedicines based on combination of phytochemicals with chemotherapeutic drugs in cancer treatment10.1016/j.addr.2022.114445 ↗
28. The strategies and techniques of drug discovery from natural products10.1016/j.pharmthera.2020.107686 ↗
29. Review targeted drug delivery systems for norcantharidin in cancer therapy10.1186/s12951-022-01703-3 ↗
30. A hybrid membrane coating nanodrug system against gastric cancer via the VEGFR2/STAT3 signaling pathway10.1039/D1TB00029B ↗
31. Pro-apoptotic and cytotoxic effects of melittin on HL-60 acute promyelocytic leukemia cells: implications for retinoid-independent therapy10.3390/molecules30204093 ↗
32. Exercise inhibits doxorubicin-induced cardiotoxicity via regulating B cells10.1161/CIRCRESAHA.123.323346 ↗
33. Living therapeutics of nonpathogenic bacteria as biosynthesis factory and active carriers for enhancing tumor-targeted therapy10.1038/s41467-025-61675-4 ↗
34. Structural and biochemical characterization of the mitomycin C repair exonuclease MrfB10.1093/nar/gkae308 ↗
35. Roles of marine microbial natural products10.1146/annurev-micro-040824-022431 ↗
36. Pharmacological reprogramming of plitidepsin as a SARS-CoV-2 inhibitor10.1016/j.mam.2025.101412 ↗
37. Natural product-derived compounds in clinical trials and drug approvals10.1039/d5np00031a ↗
38. Marine specialized metabolites: unveiling nature’s chemical treasures from the deep blue10.1016/j.trac.2024.118097 ↗
39. Microcolin H, a novel autophagy inducer, exerts potent antitumour activity by targeting PITPα/β10.1038/s41392-023-01667-2 ↗
40. Binary mineral nanoparticles enable intravascular delivery of metal ions to tumors for metalloimmunotherapy10.1038/s41467-025-68279-y ↗
41. Mineral medicine: from traditional drugs to multifunctional delivery systems10.1186/s13020-022-00577-9 ↗
42. Dynamic shielding of arsenic-loaded transferrin with calcium manganese carbonate potentiates antitumor effects via self-enhanced synergistic therapy10.1002/smtd.202500665 ↗
43. Nanodelivery of arsenic trioxide induces macrophage-governed cGAS-STING signaling to remodel immune microenvironment in hepatocellular carcinoma10.1016/j.cej.2025.159943 ↗
44. The chemistry and biology of the tetrodotoxin natural product family10.1002/anie.202502404 ↗
45. Development of a RNA-protein complex based smart drug delivery system for 9-hydroxycamptothecin10.1016/j.ijbiomac.2024.133871 ↗
46. An intratumor bacteria-targeted DNA nanocarrier for multifaceted tumor microenvironment intervention10.1016/j.mtbio.2024.101144 ↗
47. Design, synthesis, and structural evolution of pseudo-natural product IDO1 inhibitors and degraders10.1002/anie.202518753 ↗
48. Bioactive natural small molecule-tuned coassembly of photosensitive drugs for highly efficient synergistic and enhanced type I photochemotherapy10.1021/acsami.0c13164 ↗
49. Biomimetic ginsenoside Rb1 and probucol co-assembled nanoparticles for targeted atherosclerosis therapy via inhibition of oxidative stress, inflammation, and lipid deposition10.1021/acsnano.5c02492 ↗
50. Co-assembled binary polyphenol natural products for the prevention and treatment of radiation-induced skin injury10.1021/acsnano.4c08508 ↗
51. Dual-enzyme nanoassemblies of carbon dots and gold for tumor microenvironment-responsive immunotherapy in hepatocellular carcinoma10.1021/acsami.5c10705 ↗
52. Tumor immunomodulatory effects of polyphenols10.3389/fimmu.2022.1041138 ↗
53. Microbial coculture for flavonoid synthesis10.1016/j.tibtech.2020.01.008 ↗
54. Flavonoids nanostructures promising therapeutic efficiencies in colorectal cancer10.1016/j.ijbiomac.2023.124508 ↗
55. In silico and in vitro analysis of diethyl phthalate as a quorum sensing inhibitor and its antitumor evaluation against MDA-MB-231 cell lines10.1007/s11030-025-11202-w ↗
56. Intelligent nanodelivery system-generated 1O2 mediates tumor vessel normalization by activating endothelial TRPV4-eNOS signaling10.1002/smll.202200038 ↗
57. Microfluidic synthesis of CuH nanoparticles for antitumor therapy through hydrogen-enhanced apoptosis and cuproptosis10.1021/acsnano.3c12796 ↗
58. Metal-organic framework-encapsulated dihydroartemisinin nanoparticles induces apoptotic cell death in ovarian cancer by blocking ROMO1-mediated ROS production10.1186/s12951-023-01959-3 ↗
59. Nano co-delivery of plumbagin and dihydrotanshinone I reverses immunosuppressive TME of liver cancer10.1016/j.jconrel.2022.05.057 ↗
60. Bufalin inhibits hepatocellular carcinoma progression by blocking EGFR-mediated RAS-RAF-MEK-ERK pathway activation10.1186/s13046-025-03531-3 ↗
61. Application of mitochondrial miRNA-204 nanoprobes in alzheimer’s disease treatment by clearing reactive oxygen species-mediated autophagy10.1016/j.cclet.2024.110614 ↗
62. Sequential delivery of nanoformulated α-mangostin and triptolide overcomes permeation obstacles and improves therapeutic effects in pancreatic cancer10.1016/j.biomaterials.2020.119907 ↗
63. The mechanism of curcumin to protect mouse ovaries from oxidative damage by regulating AMPK/mTOR mediated autophagy10.1016/j.phymed.2024.155468 ↗
64. Cascade nanozymes based on the ‘butterfly effect’ for enhanced starvation therapy through the regulation of autophagy10.1039/D2BM00595F ↗
65. Gasdermins and pyroptosis in the kidney Nat.
66. Zhuidu formula suppresses the migratory and invasive properties of triple-negative breast cancer cells via dual signaling pathways of RhoA/ROCK and CDC42/MRCK10.1016/j.jep.2023.116644 ↗
67. Integrative analysis of immunogenic PANoptosis and experimental validation of cinobufagin-induced activation to enhance glioma immunotherapy10.1186/s13046-025-03301-1 ↗
68. Anti-glioblastoma activity of kaempferol via programmed cell death induction: involvement of autophagy and pyroptosis10.3389/fbioe.2020.614419 ↗
69. Tumor microenvironment‐activatable metal‐phenolic nanoformulations for ultrasound‐boosted ferroptosis through triple regulatory pathways10.1002/adfm.202407153 ↗
70. Engineering an advanced multicomponent pentacyclic triterpenoid nanoplatform for synergistic co-delivery of cyclin-dependent kinase 4/6 inhibitors to enhance cancer chemoimmunotherapy10.1016/j.jcis.2025.138203 ↗
71. IL-15 functionalized biomimetic hybrid mRNA vaccine for enhanced NSCLC immunotherapy via synergistic activation of T cells and NK cells10.1016/j.mtbio.2025.101914 ↗
72. Enhanced cancer therapy of celastrol in vitro and in vivo by smart dendrimers delivery with specificity and biosafety10.1016/j.cej.2019.123228 ↗
73. Ginsenoside Rg3-engineered exosomes as effective delivery platform for potentiated chemotherapy and photoimmunotherapy of glioblastoma10.1016/j.cej.2023.144692 ↗
74. Astragalus membranaceus polysaccharides potentiate the growth-inhibitory activity of immune checkpoint inhibitors against pulmonary metastatic melanoma in mice10.1016/j.ijbiomac.2021.05.073 ↗
75. Nucleus-targeted sonosensitizer activates the cGAS-STING pathway for tumor sonodynamic immunotherapy10.1021/acsabm.4c00682 ↗
76. Platycodon grandiflorum triggers antitumor immunity by restricting PD-1 expression of CD8 T cells in local tumor microenvironment10.3389/fphar.2022.774440 ↗
77. Nano-assemblies overcome cancer multidrug resistance for effectively synergistic chemo-immuno-oncotherapy10.1016/j.cej.2024.151437 ↗
78. Paclitaxel-loaded ginsenoside Rg3 liposomes for drug-resistant cancer therapy by dual targeting of the tumor microenvironment and cancer cells10.1016/j.jare.2022.09.007 ↗
79. Astragaloside IV enhances cisplatin chemosensitivity in hepatocellular carcinoma by suppressing MRP210.1016/j.ejps.2020.105325 ↗
80. Immune exosomes loading self-assembled nanomicelles traverse the blood-brain barrier for chemo-immunotherapy against glioblastoma10.1021/acsnano.2c10219 ↗
81. Genetically engineered cellular nanoparticles loaded with curcuminoids for cancer immunotherapy10.7150/thno.99033 ↗
82. Exosome-liposome hybrid nanoparticle codelivery of TP and miR497 conspicuously overcomes chemoresistant ovarian cancer10.1186/s12951-022-01628-9 ↗
83. Triptolide induces apoptosis and cytoprotective autophagy by ROS accumulation via directly targeting peroxiredoxin 2 in gastric cancer cells10.1016/j.canlet.2024.216622 ↗
84. Dihydroartemisinin synergistically promotes the antileukemic activity of venetoclax by downregulating mcl-1 in acute myeloid leukemia cells10.1182/blood-2023-184408 ↗
85. Sensitizing sorafenib to hepatocellular carcinoma with dual-targeted and pH-responsive nanodrugs via overcoming the hypoxia tumor microenvironment10.1016/j.cej.2024.157231 ↗
86. Targeting PKM2 signaling cascade with salvianic acid a normalizes tumor blood vessels to facilitate chemotherapeutic drug delivery10.1016/j.apsb.2024.02.003 ↗
87. Gambogic acid impairs tumor angiogenesis by targeting YAP/STAT3 signaling axis10.1002/ptr.6350 ↗
88. Immunomodulatory pd-FePorP nanozyme for inhibition of tumor invasion and metastasis by reinforced ferroptosis and specific epithelial-mesenchymal reversal10.1016/j.cej.2024.158682 ↗
89. Honokiol inhibits epithelial-mesenchymal transition and hepatic fibrosis via activation of ecadherin/GSK3β/JNK and inhibition of AKT/ERK/p38/β-catenin/TMPRSS4 signaling axis10.1002/ptr.7871 ↗
90. Dihydroartemisinin inhibits the development of colorectal cancer by GSK-3β/TCF7/MMP9 pathway and synergies with capecitabine10.1016/j.canlet.2023.216596 ↗
91. Rutin gel with bone graft accelerates bone formation in a rabbit model by inhibiting MMPs and enhancing collagen activities10.3390/ph16050774 ↗
92. Emodin reduces breast cancer lung metastasis by suppressing macrophage-induced breast cancer cell epithelial-mesenchymal transition and cancer stem cell formation10.7150/thno.45395 ↗
93. Magnolol regulates miR-200c-3p to inhibit epithelial-mesenchymal transition and retinoblastoma progression by modulating the ZEB1/E-cadherin axis in vitro and in vivo10.1016/j.phymed.2022.154597 ↗
94. Nanobiomaterial-enabled boron delivery systems and innovative strategies for revolutionizing BNCT10.7150/thno.126209 ↗
95. Paclitaxel/luteolin coloaded dual‐functional liposomes for esophageal cancer therapy10.1002/advs.202411930 ↗
96. Preparation of hierarchically targetable astragalus polysaccharide lipid nanoparticles and study on their therapeutic effect on orthotopic colon cancer10.1016/j.mtbio.2025.102509 ↗
97. Dual-targeted biomimetic nanoparticles for enhanced delivery of polyphyllin B synergistically induce ferroptosis and immunogenic cell death in gastric cancer10.1021/acsami.5c13198 ↗
98. Icaritin represses autophagy to promote colorectal cancer cell apoptosis and sensitized low-temperature photothermal therapy via targeting HSP90-TXNDC9 interactions10.1002/advs.202412953 ↗
99. Small-size Ti3C2Tx MXene nanosheets coated with metal-polyphenol nanodots for enhanced cancer photothermal therapy and anti-inflammation10.1016/j.actbio.2023.01.049 ↗
100. Hyaluronic acid/dextran-based polymeric micelles co-delivering ursolic acid and doxorubicin to mitochondria for potentiating chemotherapy in MDR cancer10.1016/j.carbpol.2024.121897 ↗